Non-small cell lung cancer · 5 regimens
Cost vs Efficacy · 1 point
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Ipilimumab and Nivolumab Variant #01 Partial | — | R 78 615 | 42d | ~11.5 mo | ~29.2 mo | ~9 | ~R 707 538 PFS proxy · indirect | 13 |
VIP Variant #01 | — | R 10 535 | 21d | — | — | — | — | — |
CAP (Platinol) Partial | — | — | — | — | — | — | — | — |
Carboplatin and Paclitaxel (CP) and Vadimezan Partial | — | — | — | — | 13.4 mo | — | — | 1 |
PCG (Carboplatin) Partial | — | — | — | — | — | — | — | — |
5 of 5 regimens shown